Holen Sie sich die Stockscreener-App
9.61
3.11%
0.29
Cybin Inc Aktie (CYBN) Neueste Nachrichten
Objective long/short (CYBN) Report - Stock Traders Daily
Cybin (FRA:R7E) Total Inventories : €0.00 Mil (As of Sep. 2024) - GuruFocus.com
Facet Life Sciences Partners with Cybin to Advance Mental Health Therapies - MSN
Cybin Reveals Promising Results in Depression Treatment - TipRanks
Cybin's Breakthrough Clinical Data Shows 100% Response Rate in Depression Treatment Study - StockTitan
Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results - Yahoo Finance
(CYBN) Investment Report - Stock Traders Daily
PEAK6 Investments LLC Sells 420,512 Shares of Cybin Inc. (NYSE:CYBN) - MarketBeat
Cybin Stock In Focus On MDD Treatment's 'Breakthrough’ Efficacy: Retail Turns Extremely Bullish - MSN
Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024 - Chatham-Kent This Week
Cybin to Discuss Breakthrough Treatments at Fireside Chat - TipRanks
TANG CAPITAL MANAGEMENT LLC Increases Stake in Cybin Inc - GuruFocus.com
Psychedelic Drugs Market Growth in Future Scope 2024-2031 | - openPR
Cybin (FRA:R7E) 3-Year EPS without NRI Growth Rate : 6.10% (As of Sep. 2024) - GuruFocus.com
Cybin (FRA:R7E) 50-Day SMA : €9.05 (As of Nov. 30, 2024) - GuruFocus.com
Cybin (OTCMKTS:CYBN) Stock Price Down 4.3%What's Next? - MarketBeat
FDA's Psychedelic Reckoning - Life Science Leader Magazine
Cybin (STU:R7E) Earnings Yield (Joel Greenblatt) % : -151.52% (As of Sep. 2024) - GuruFocus.com
Cybin Inc. Advances in Mental Health Treatments - TipRanks
Cybin (STU:R7E) Change In Receivables : €-1.00 Mil (TTM As of Sep. 2024) - GuruFocus.com
What is Bloom Burton's Estimate for Cybin FY2025 Earnings? - MarketBeat
HC Wainwright Brokers Decrease Earnings Estimates for Cybin - MarketBeat
Cybin launches new program phase to treat Major Depressive Disorder - MSN
Breakthrough Therapy Shows Promising Long-Term Results for Depression - Streetwise Reports
Cybin’s Breakthrough: Psychedelic Depression Drug CYB003 Sustains 12-Month Symptom Remission in Major Depressive Disorder - geneonline
H.C. Wainwright reiterates Buy on Cybin stock, sees strong potential for CYB003 in MDD - Investing.com
Cybin reports sustained depression treatment effects By Investing.com - Investing.com Canada
Cybin (NYSE:CYBN) Receives Buy Rating from HC Wainwright - MarketBeat
Cybin Reports Positive Phase 2 Data for CYB003 - The Dales Report
Cybin’s CYB003 Shows Promising Results for Depression - TipRanks
Cybin reports sustained depression treatment effects - Investing.com
Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder - Business Wire
Cybin posts second-quarter loss widens as clinical trials advance - Green Market Report
Canaccord Genuity Group Lowers Cybin (NYSE:CYBN) Price Target to $86.00 - MarketBeat
Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024 - BioSpace
Cybin to Present Promising CYB003 Study Results - TipRanks
Cybin to Showcase Promising Depression Treatment Progress - TipRanks
CYBNCybin Inc. Latest Stock News & Market Updates - StockTitan
Cybin Inc (CYBN-NE) QuotePress Release - The Globe and Mail
Cybin launches new program phase to treat Major Depressive Disorder | 2024-11-13 | Investing News - Stockhouse Publishing
Cybin’s Phase 3 Trials and Financial Update - TipRanks
Can Canada’s psychedelic drug developers shake off the sector’s bad trip? - The Globe and Mail
Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results - StreetInsider.com
Cybin Inc. Begins Phase 3 Trials, Betting Big On CYB003 To Treat Depression - Benzinga
What might RFK Jr’s psychedelic strategy look like? - Proactive Investors USA
Cybin Faces Key Data Readouts For Major Depressive Disorder, Generalized Anxiety Disorder - RTTNews
Learn to Evaluate (CYBN) using the Charts - Stock Traders Daily
Cybin Inc. (NYSE:CYBN) Stake Lowered by Rosalind Advisors Inc. - MarketBeat
Cybin (OTCMKTS:CYBN) Trading Up 0.2%Here's What Happened - MarketBeat
Cybin, Inc.Why Compass Pathways Is No Compass for Cybin's Progression Prospects - Smartkarma
PDS Planning Inc Sells 885,540 Shares of Cybin Inc. (NYSE:CYBN) - MarketBeat
2.88%
2.65%
Kapitalisierung:
|
Volumen (24h):